Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06844383 · ClinicalTrials.gov registry record · Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
A Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Prostate Cancer Clinical Trials Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 2
- Study locations
NCT06844383: Recruiting Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Prostate Cancer Clinical Trials Consortium.
NCT06844383 is a Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer) that is actively recruiting participants, run by Prostate Cancer Clinical Trials Consortium. The registered enrollment target is 126 participants, roughly in line with the 121-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06844383, a Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), is actively recruiting participants, sponsored by Prostate Cancer Clinical Trials Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Primary Outcome
To compare the efficacy of talazoparib + enzalutamide to talazoparib alone as measured by rPFS as assessed by the Investigator.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Talazoparib with enzalutamide
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-10 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What NCT06844383 shows while recruiting
NCT06844383 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 121-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target.
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT06844383 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06844383 about?
NCT06844383 is a clinical study titled "A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate". The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received ab...
What is the current status of trial NCT06844383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-10. Estimated completion is 2030-03.
What conditions does trial NCT06844383 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer).
What interventions are being tested in trial NCT06844383?
The interventions under investigation include: Talazoparib (DRUG), Talazoparib with enzalutamide (DRUG).
Who is sponsoring clinical trial NCT06844383?
This trial is sponsored by Prostate Cancer Clinical Trials Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06844383 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06844383's enrollment target sits among peer trials
126 2nd of 13 the highest of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
RECRUITING · Phase 2
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia